<DOC>
	<DOCNO>NCT01094678</DOCNO>
	<brief_summary>The Zilver PTX Registry Study prospective , non-randomized , open-label , multicenter single-arm study enrol patient Europe , Asia , North America de novo restenotic ( include in-stent restenosis ) lesions above-the-knee femoropopliteal artery ( SFA ) . The primary endpoint study event-free survival ( EFS ) 6 month .</brief_summary>
	<brief_title>Zilver® PTX™ Global Registry</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>stenosis abovetheknee femoropopliteal artery appropriate size location lesion pregnant breast feeding failure inability give inform consent simultaneously participate another drug device study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Peripheral Aterial Disease ( PAD )</keyword>
	<keyword>Peripheral Vascular Disease</keyword>
	<keyword>Drug-Eluting Stent</keyword>
	<keyword>Drug-Coated Stent</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
</DOC>